|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.92 SEK | +2.16% |
|
+22.54% | -16.28% |
| 23/06 | Citadel Back as Public Short Seller in Synact Pharma | FW |
| 18/06 | Edison Maintains Its Valuation for Synact Pharma After Trial Results | FW |
| Market Cap | 100.68Cr 10Cr 9.13Cr 8.39Cr 7.82Cr 15Cr 993.92Cr 15Cr 39Cr 488.57Cr 39Cr 38Cr 1.68TCr | P/E 2026 * |
-12.7x | P/E 2027 * | -24.9x |
|---|---|---|---|---|---|
| Enterprise Value | 99Cr 10Cr 8.97Cr 8.24Cr 7.68Cr 15Cr 976.67Cr 15Cr 38Cr 480.08Cr 39Cr 38Cr 1.65TCr | EV / Sales 2026 * |
7.13x | EV / Sales 2027 * | 48.8x |
| Free-Float |
70.28% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: SynAct Pharma AB
| 1 day | +2.16% | ||
| 1 week | +22.54% | ||
| Current month | -10.12% | ||
| 1 month | +36.90% | ||
| 3 months | +3.84% | ||
| 6 months | -15.72% | ||
| Current year | -16.28% |
| 1 week | 15.5 |  | 22.25 |
| 1 month | 7.05 | | 22.25 |
| Current year | 7.05 | | 24.4 |
| 1 year | 7.05 | | 25.3 |
| 3 years | 4.98 | | 124.6 |
| 5 years | 4.98 | | 146 |
| 10 years | 4.75 | | 146 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jeppe Øvlesen
CEO | Chief Executive Officer | 64 | 01/01/2014 |
Ann Kristin Led
DFI | Director of Finance/CFO | - | 01/03/2026 |
Kirsten Harting
CTO | Chief Tech/Sci/R&D Officer | - | 15/02/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Jeppe Øvlesen
BRD | Director/Board Member | 64 | 20/03/2024 |
Anders Kronborg
CHM | Chairman | 62 | 20/03/2024 |
Sten Scheibye
BRD | Director/Board Member | 74 | 20/03/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 10/03 | Buy | Chairman | 2,750 | 0.0052% | ||
| 09/03 | Buy | Executive/Senior Manager | 1,500 | 0.0028% | ||
| 09/03 | Quantass ApS
| Buy | Company | 7,900 | 0.0148% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.16% | +22.54% | -10.75% | -74.71% | 10Cr | |
| +1.86% | +0.48% | +55.50% | +163.08% | 1,08200Cr | |
| +3.57% | +3.29% | +68.60% | +61.03% | 63TCr | |
| +3.99% | +3.05% | +37.93% | +93.37% | 46TCr | |
| +3.86% | +1.64% | +32.57% | +24.89% | 34TCr | |
| -0.56% | +0.96% | +41.67% | +39.35% | 30TCr | |
| -0.08% | +1.30% | +32.15% | +44.48% | 29TCr | |
| -1.54% | +2.81% | -25.35% | -39.61% | 22TCr | |
| +3.55% | +4.41% | +25.45% | +66.28% | 20TCr | |
| +4.21% | +2.65% | +17.47% | +71.11% | 16TCr | |
| Average | +2.10% | +6.37% | +27.52% | +44.93% | 36.93TCr | |
| Weighted average by Cap. | +2.25% | +5.53% | +42.31% | +83.30% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 14Cr 1.44Cr 1.26Cr 1.16Cr 1.08Cr 2.04Cr 136.97Cr 2.07Cr 5.39Cr 67Cr 5.4Cr 5.28Cr 232.01Cr | 2.12Cr 21.93L 19.17L 17.62L 16.42L 31.15L 21Cr 31.62L 82.22L 10Cr 82.31L 80.54L 35Cr |
| Net income | 5.22Cr 54.1L 47.29L 43.46L 40.51L 76.84L 52Cr 78L 2.03Cr 25Cr 2.03Cr 1.99Cr 87Cr | -2.6Cr -27L -23.61L -21.69L -20.22L -38.36L -26Cr -38.94L -1.01Cr -13Cr -1.01Cr -99.19L -44Cr |
| Net Debt | -1.75Cr -18.12L -15.84L -14.56L -13.57L -25.74L -17Cr -26.13L -67.95L -8.48Cr -68.03L -66.57L -29Cr | 2.49Cr 25.78L 22.53L 20.71L 19.3L 36.61L 25Cr 37.17L 96.64L 12Cr 96.75L 94.67L 42Cr |
Employees
8
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/26/03 | SEK 18.92 | +2.16% | 2,02,458 |
| 02/26/02 | SEK 18.52 | -6.56% | 3,28,846 |
| 01/26/01 | SEK 19.82 | -5.84% | 5,80,556 |
| 30/26/30 | SEK 21.05 | +14.40% | 8,23,897 |
| 29/26/29 | SEK 18.40 | +19.17% | 6,05,579 |
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SYNACT Stock
Select your edition
All financial news and data tailored to specific country editions
